Elizabeth Brickley
Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 54 | 2025 | 165 | 11.390 |
Why?
| | Zika Virus | 42 | 2025 | 128 | 8.020 |
Why?
| | Microcephaly | 32 | 2025 | 98 | 4.910 |
Why?
| | Pregnancy Complications, Infectious | 29 | 2025 | 394 | 3.710 |
Why?
| | Poliomyelitis | 9 | 2025 | 37 | 2.980 |
Why?
| | Brazil | 54 | 2025 | 167 | 2.720 |
Why?
| | Poliovirus Vaccine, Oral | 6 | 2025 | 25 | 2.300 |
Why?
| | Poliovirus Vaccine, Inactivated | 6 | 2024 | 28 | 2.150 |
Why?
| | Poliovirus | 6 | 2025 | 85 | 2.040 |
Why?
| | Antibodies, Viral | 10 | 2025 | 625 | 1.540 |
Why?
| | Arboviruses | 2 | 2022 | 16 | 1.530 |
Why?
| | Leprosy | 8 | 2025 | 24 | 1.410 |
Why?
| | Dengue | 3 | 2022 | 80 | 1.370 |
Why?
| | Immunity, Mucosal | 7 | 2025 | 97 | 1.340 |
Why?
| | Malaria | 5 | 2019 | 63 | 1.300 |
Why?
| | Prenatal Exposure Delayed Effects | 11 | 2025 | 605 | 1.150 |
Why?
| | Epidemics | 4 | 2021 | 89 | 1.140 |
Why?
| | Anemia | 4 | 2019 | 170 | 1.090 |
Why?
| | Immunoglobulin A | 8 | 2025 | 211 | 1.050 |
Why?
| | Infant | 43 | 2025 | 9465 | 0.960 |
Why?
| | Pregnancy | 44 | 2025 | 6763 | 0.950 |
Why?
| | Antibodies, Neutralizing | 9 | 2025 | 286 | 0.930 |
Why?
| | Disease Outbreaks | 9 | 2024 | 395 | 0.920 |
Why?
| | Vaccines, Attenuated | 3 | 2022 | 132 | 0.920 |
Why?
| | Fetal Blood | 3 | 2017 | 327 | 0.920 |
Why?
| | Chikungunya Fever | 2 | 2024 | 79 | 0.920 |
Why?
| | Virus Diseases | 3 | 2021 | 212 | 0.760 |
Why?
| | Chikungunya virus | 2 | 2024 | 80 | 0.750 |
Why?
| | Cohort Studies | 26 | 2025 | 5742 | 0.750 |
Why?
| | Feces | 4 | 2022 | 484 | 0.740 |
Why?
| | Arbovirus Infections | 1 | 2022 | 21 | 0.740 |
Why?
| | Vaccines, Inactivated | 2 | 2019 | 68 | 0.740 |
Why?
| | Infant, Newborn | 32 | 2025 | 6079 | 0.720 |
Why?
| | Child, Preschool | 36 | 2025 | 11074 | 0.710 |
Why?
| | Mosquito Vectors | 2 | 2022 | 30 | 0.700 |
Why?
| | Humans | 109 | 2025 | 137585 | 0.700 |
Why?
| | Malaria Vaccines | 2 | 2017 | 8 | 0.670 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 36 | 0.660 |
Why?
| | Intestinal Mucosa | 3 | 2025 | 623 | 0.650 |
Why?
| | Socioeconomic Factors | 13 | 2025 | 1289 | 0.640 |
Why?
| | Workplace | 4 | 2024 | 261 | 0.610 |
Why?
| | Female | 73 | 2025 | 73304 | 0.600 |
Why?
| | Coinfection | 1 | 2020 | 137 | 0.600 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 373 | 0.590 |
Why?
| | Coronavirus Infections | 2 | 2020 | 364 | 0.590 |
Why?
| | Influenza Vaccines | 2 | 2019 | 539 | 0.550 |
Why?
| | Anopheles | 1 | 2016 | 16 | 0.520 |
Why?
| | Malaria, Falciparum | 1 | 2016 | 27 | 0.520 |
Why?
| | Hepcidins | 1 | 2016 | 22 | 0.510 |
Why?
| | Vaccination | 6 | 2024 | 1381 | 0.500 |
Why?
| | Fetal Diseases | 3 | 2021 | 173 | 0.440 |
Why?
| | Iron | 1 | 2016 | 313 | 0.430 |
Why?
| | Young Adult | 22 | 2025 | 13209 | 0.420 |
Why?
| | Influenza, Human | 1 | 2019 | 622 | 0.410 |
Why?
| | Adult | 37 | 2025 | 37929 | 0.400 |
Why?
| | Male | 44 | 2025 | 67762 | 0.400 |
Why?
| | Pandemics | 2 | 2020 | 1639 | 0.390 |
Why?
| | Nervous System Malformations | 2 | 2023 | 42 | 0.380 |
Why?
| | Cross-Sectional Studies | 11 | 2025 | 5472 | 0.370 |
Why?
| | Immunoglobulin G | 6 | 2025 | 893 | 0.370 |
Why?
| | Leprosy, Multibacillary | 2 | 2021 | 2 | 0.350 |
Why?
| | Tuberculosis | 2 | 2025 | 279 | 0.350 |
Why?
| | Fetus | 2 | 2021 | 806 | 0.350 |
Why?
| | Exanthema | 2 | 2023 | 78 | 0.350 |
Why?
| | Child | 25 | 2024 | 21935 | 0.340 |
Why?
| | Cryptorchidism | 2 | 2020 | 15 | 0.340 |
Why?
| | Incidence | 11 | 2025 | 2804 | 0.320 |
Why?
| | Biomarkers | 5 | 2020 | 4149 | 0.310 |
Why?
| | Poliovirus Vaccines | 2 | 2019 | 6 | 0.290 |
Why?
| | Adolescent | 17 | 2025 | 21513 | 0.290 |
Why?
| | Virus Shedding | 4 | 2021 | 48 | 0.280 |
Why?
| | Neurodevelopmental Disorders | 2 | 2020 | 181 | 0.270 |
Why?
| | Maternal Exposure | 2 | 2021 | 190 | 0.270 |
Why?
| | Prospective Studies | 14 | 2025 | 7604 | 0.270 |
Why?
| | Infant Mortality | 3 | 2024 | 116 | 0.270 |
Why?
| | Parturition | 3 | 2023 | 71 | 0.260 |
Why?
| | Urban Population | 2 | 2020 | 479 | 0.260 |
Why?
| | Pregnancy Outcome | 4 | 2025 | 416 | 0.260 |
Why?
| | Middle Aged | 19 | 2025 | 33479 | 0.250 |
Why?
| | Cytokines | 1 | 2014 | 2085 | 0.250 |
Why?
| | Social Segregation | 1 | 2025 | 4 | 0.240 |
Why?
| | Immunoglobulin M | 4 | 2022 | 289 | 0.240 |
Why?
| | Public Housing | 1 | 2025 | 9 | 0.240 |
Why?
| | Adenoids | 2 | 2024 | 12 | 0.230 |
Why?
| | Risk | 3 | 2020 | 912 | 0.230 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2025 | 54 | 0.230 |
Why?
| | Risk Factors | 13 | 2025 | 10388 | 0.230 |
Why?
| | Case-Control Studies | 4 | 2021 | 3556 | 0.220 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2025 | 67 | 0.220 |
Why?
| | Pharynx | 1 | 2024 | 59 | 0.220 |
Why?
| | Language Development Disorders | 2 | 2022 | 41 | 0.220 |
Why?
| | Income | 1 | 2025 | 202 | 0.220 |
Why?
| | Prevalence | 6 | 2023 | 2734 | 0.210 |
Why?
| | Transients and Migrants | 1 | 2023 | 24 | 0.210 |
Why?
| | Hospitalization | 2 | 2025 | 2199 | 0.210 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2025 | 148 | 0.210 |
Why?
| | Americas | 2 | 2020 | 28 | 0.210 |
Why?
| | Bayes Theorem | 2 | 2022 | 405 | 0.210 |
Why?
| | Epilepsies, Partial | 2 | 2023 | 50 | 0.210 |
Why?
| | Electroencephalography | 2 | 2023 | 423 | 0.200 |
Why?
| | Racism | 1 | 2025 | 135 | 0.200 |
Why?
| | Meta-Analysis as Topic | 2 | 2021 | 186 | 0.200 |
Why?
| | Belgium | 1 | 2022 | 13 | 0.200 |
Why?
| | Smokers | 1 | 2023 | 145 | 0.200 |
Why?
| | Respiratory Tract Infections | 2 | 2024 | 390 | 0.200 |
Why?
| | Viruses, Unclassified | 1 | 2022 | 2 | 0.200 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2025 | 652 | 0.190 |
Why?
| | United Kingdom | 2 | 2020 | 318 | 0.190 |
Why?
| | Urinary Tract | 1 | 2022 | 51 | 0.190 |
Why?
| | Hospital Records | 1 | 2021 | 12 | 0.180 |
Why?
| | Family Characteristics | 2 | 2020 | 191 | 0.180 |
Why?
| | Nervous System | 1 | 2022 | 67 | 0.180 |
Why?
| | Hearing Loss | 1 | 2025 | 221 | 0.180 |
Why?
| | Child Mortality | 1 | 2021 | 16 | 0.180 |
Why?
| | Epilepsy | 2 | 2023 | 333 | 0.180 |
Why?
| | Serogroup | 2 | 2018 | 44 | 0.180 |
Why?
| | Orchiopexy | 1 | 2020 | 6 | 0.180 |
Why?
| | Antibody Formation | 1 | 2022 | 298 | 0.170 |
Why?
| | Control Groups | 1 | 2020 | 11 | 0.170 |
Why?
| | Cerebral Palsy | 1 | 2023 | 107 | 0.170 |
Why?
| | Public Assistance | 1 | 2020 | 20 | 0.170 |
Why?
| | Language Development | 1 | 2021 | 61 | 0.170 |
Why?
| | Air Pollution | 1 | 2024 | 316 | 0.170 |
Why?
| | Epidemiologic Research Design | 1 | 2020 | 29 | 0.170 |
Why?
| | Betacoronavirus | 2 | 2020 | 270 | 0.170 |
Why?
| | Endocrine System Diseases | 1 | 2020 | 35 | 0.170 |
Why?
| | Motor Skills | 1 | 2021 | 97 | 0.170 |
Why?
| | Central Nervous System Diseases | 1 | 2021 | 69 | 0.170 |
Why?
| | Pregnancy, Twin | 1 | 2020 | 19 | 0.170 |
Why?
| | Leprostatic Agents | 1 | 2020 | 5 | 0.170 |
Why?
| | Viral Vaccines | 1 | 2021 | 98 | 0.170 |
Why?
| | Breast Feeding | 1 | 2024 | 440 | 0.170 |
Why?
| | Malformations of Cortical Development | 1 | 2020 | 13 | 0.160 |
Why?
| | Tanzania | 2 | 2019 | 58 | 0.160 |
Why?
| | England | 3 | 2024 | 97 | 0.160 |
Why?
| | Cross-Cultural Comparison | 1 | 2020 | 86 | 0.160 |
Why?
| | Developing Countries | 2 | 2019 | 307 | 0.160 |
Why?
| | Cesarean Section | 1 | 2021 | 184 | 0.160 |
Why?
| | Plasmodium | 1 | 2019 | 13 | 0.160 |
Why?
| | Respiratory Sounds | 1 | 2020 | 125 | 0.160 |
Why?
| | Coronavirus | 1 | 2020 | 47 | 0.160 |
Why?
| | Receptors, Complement 3b | 1 | 2019 | 84 | 0.160 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2019 | 38 | 0.160 |
Why?
| | Protozoan Proteins | 2 | 2017 | 82 | 0.160 |
Why?
| | Air Pollutants | 1 | 2024 | 430 | 0.160 |
Why?
| | Bangladesh | 1 | 2019 | 56 | 0.160 |
Why?
| | Prenatal Diagnosis | 1 | 2021 | 201 | 0.160 |
Why?
| | Administration, Intranasal | 1 | 2019 | 90 | 0.160 |
Why?
| | Urbanization | 1 | 2019 | 29 | 0.160 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 45 | 0.160 |
Why?
| | Infant, Newborn, Diseases | 1 | 2021 | 113 | 0.150 |
Why?
| | Birth Certificates | 1 | 2019 | 10 | 0.150 |
Why?
| | Travel | 1 | 2020 | 130 | 0.150 |
Why?
| | N-Acetylneuraminic Acid | 1 | 2019 | 12 | 0.150 |
Why?
| | Death Certificates | 1 | 2019 | 30 | 0.150 |
Why?
| | Intestines | 2 | 2021 | 357 | 0.150 |
Why?
| | Chile | 1 | 2018 | 24 | 0.150 |
Why?
| | Esophageal Neoplasms | 1 | 2022 | 321 | 0.150 |
Why?
| | Deglutition Disorders | 1 | 2020 | 143 | 0.150 |
Why?
| | Rural Population | 2 | 2021 | 563 | 0.150 |
Why?
| | Follow-Up Studies | 7 | 2023 | 5131 | 0.150 |
Why?
| | Developmental Disabilities | 1 | 2021 | 263 | 0.150 |
Why?
| | Comorbidity | 2 | 2020 | 1622 | 0.150 |
Why?
| | Medical Record Linkage | 1 | 2019 | 65 | 0.150 |
Why?
| | Communicable Diseases | 1 | 2020 | 159 | 0.140 |
Why?
| | Spasms, Infantile | 1 | 2020 | 123 | 0.140 |
Why?
| | Immunoglobulin D | 1 | 2018 | 30 | 0.140 |
Why?
| | Sporozoites | 1 | 2017 | 1 | 0.140 |
Why?
| | Plasmodium falciparum | 1 | 2017 | 30 | 0.140 |
Why?
| | Research | 1 | 2021 | 451 | 0.140 |
Why?
| | Nervous System Diseases | 1 | 2020 | 266 | 0.140 |
Why?
| | Rectus Abdominis | 1 | 2017 | 17 | 0.140 |
Why?
| | Patient Participation | 1 | 2021 | 420 | 0.140 |
Why?
| | Milk, Human | 1 | 2019 | 158 | 0.130 |
Why?
| | Gestational Age | 4 | 2022 | 910 | 0.130 |
Why?
| | Databases, Factual | 2 | 2021 | 1357 | 0.130 |
Why?
| | Endothelium | 1 | 2017 | 123 | 0.130 |
Why?
| | Esophageal Motility Disorders | 1 | 2016 | 27 | 0.130 |
Why?
| | Sepsis | 1 | 2023 | 617 | 0.130 |
Why?
| | Registries | 5 | 2025 | 2035 | 0.130 |
Why?
| | Asthma | 2 | 2020 | 2295 | 0.130 |
Why?
| | Arsenic | 1 | 2017 | 64 | 0.130 |
Why?
| | Free Tissue Flaps | 1 | 2017 | 52 | 0.130 |
Why?
| | Esophagitis | 1 | 2016 | 67 | 0.130 |
Why?
| | Smoking | 1 | 2023 | 1627 | 0.120 |
Why?
| | Body Composition | 1 | 2019 | 684 | 0.120 |
Why?
| | Adenocarcinoma | 1 | 2022 | 940 | 0.120 |
Why?
| | Mammaplasty | 1 | 2017 | 105 | 0.120 |
Why?
| | Social Determinants of Health | 1 | 2019 | 267 | 0.120 |
Why?
| | Deficiency Diseases | 1 | 2014 | 10 | 0.120 |
Why?
| | Child Nutrition Disorders | 1 | 2014 | 20 | 0.110 |
Why?
| | Wasting Syndrome | 1 | 2014 | 13 | 0.110 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2014 | 43 | 0.110 |
Why?
| | Longitudinal Studies | 4 | 2023 | 2844 | 0.110 |
Why?
| | Esophagus | 1 | 2016 | 255 | 0.110 |
Why?
| | Lymphocytes | 1 | 2016 | 397 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2019 | 527 | 0.110 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2014 | 87 | 0.110 |
Why?
| | Dendritic Cells | 1 | 2017 | 483 | 0.110 |
Why?
| | Erythrocytes | 1 | 2019 | 700 | 0.110 |
Why?
| | Tissue Donors | 1 | 2017 | 425 | 0.110 |
Why?
| | Cognition | 1 | 2021 | 1153 | 0.100 |
Why?
| | Ecuador | 2 | 2024 | 11 | 0.100 |
Why?
| | Interleukins | 1 | 2014 | 250 | 0.100 |
Why?
| | Animals | 5 | 2022 | 36940 | 0.090 |
Why?
| | Skin | 1 | 2016 | 752 | 0.090 |
Why?
| | Cause of Death | 2 | 2025 | 434 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2016 | 1050 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2017 | 900 | 0.090 |
Why?
| | Interferon-gamma | 1 | 2014 | 789 | 0.090 |
Why?
| | Diet | 1 | 2019 | 1278 | 0.090 |
Why?
| | Feeding Behavior | 1 | 2016 | 654 | 0.090 |
Why?
| | Neuroimaging | 2 | 2023 | 259 | 0.090 |
Why?
| | Occupational Exposure | 2 | 2024 | 341 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2022 | 15657 | 0.080 |
Why?
| | Growth Disorders | 2 | 2024 | 86 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1242 | 0.080 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2021 | 184 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2017 | 1996 | 0.080 |
Why?
| | Latin America | 2 | 2020 | 93 | 0.070 |
Why?
| | Cerebral Cortex | 2 | 2023 | 433 | 0.070 |
Why?
| | RNA, Viral | 2 | 2023 | 656 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2020 | 1062 | 0.070 |
Why?
| | Treatment Outcome | 4 | 2025 | 10811 | 0.070 |
Why?
| | Spatial Analysis | 1 | 2025 | 20 | 0.060 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 2025 | 4 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5778 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2025 | 76 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2017 | 2654 | 0.060 |
Why?
| | Serum | 1 | 2025 | 59 | 0.060 |
Why?
| | Ventilation | 1 | 2024 | 44 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 2836 | 0.050 |
Why?
| | Nasal Mucosa | 1 | 2024 | 107 | 0.050 |
Why?
| | Manufacturing and Industrial Facilities | 1 | 2023 | 2 | 0.050 |
Why?
| | Contact Tracing | 1 | 2023 | 27 | 0.050 |
Why?
| | Alpha Rhythm | 1 | 2023 | 8 | 0.050 |
Why?
| | Theta Rhythm | 1 | 2023 | 12 | 0.050 |
Why?
| | Plastics | 1 | 2023 | 42 | 0.050 |
Why?
| | Sleep Stages | 1 | 2023 | 47 | 0.050 |
Why?
| | Health Status Indicators | 1 | 2024 | 171 | 0.050 |
Why?
| | Eye Movements | 1 | 2023 | 67 | 0.050 |
Why?
| | Information Storage and Retrieval | 1 | 2023 | 118 | 0.050 |
Why?
| | DNA Viruses | 1 | 2022 | 14 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2022 | 34 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2022 | 118 | 0.050 |
Why?
| | Wakefulness | 1 | 2023 | 125 | 0.050 |
Why?
| | Urodynamics | 1 | 2022 | 44 | 0.050 |
Why?
| | Particulate Matter | 1 | 2024 | 315 | 0.050 |
Why?
| | Esophagectomy | 1 | 2022 | 131 | 0.050 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2022 | 109 | 0.050 |
Why?
| | Age of Onset | 1 | 2023 | 518 | 0.040 |
Why?
| | Evoked Potentials, Auditory | 1 | 2022 | 180 | 0.040 |
Why?
| | Lithuania | 1 | 2021 | 1 | 0.040 |
Why?
| | Parity | 1 | 2021 | 126 | 0.040 |
Why?
| | Population Groups | 1 | 2021 | 62 | 0.040 |
Why?
| | Diagnostic Techniques, Surgical | 1 | 2020 | 2 | 0.040 |
Why?
| | Caribbean Region | 1 | 2020 | 28 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2023 | 267 | 0.040 |
Why?
| | Testicular Diseases | 1 | 2020 | 7 | 0.040 |
Why?
| | Pregnancy, High-Risk | 1 | 2020 | 14 | 0.040 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 30 | 0.040 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 30 | 0.040 |
Why?
| | Infection Control | 1 | 2022 | 167 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2020 | 82 | 0.040 |
Why?
| | Delivery, Obstetric | 1 | 2021 | 144 | 0.040 |
Why?
| | Hypertrophy | 1 | 2021 | 133 | 0.040 |
Why?
| | Fetal Death | 1 | 2020 | 55 | 0.040 |
Why?
| | Causality | 1 | 2020 | 126 | 0.040 |
Why?
| | World Health Organization | 1 | 2020 | 123 | 0.040 |
Why?
| | Maternal Age | 1 | 2020 | 129 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 404 | 0.040 |
Why?
| | Treatment Adherence and Compliance | 1 | 2020 | 26 | 0.040 |
Why?
| | Macaca fascicularis | 1 | 2019 | 65 | 0.040 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 97 | 0.040 |
Why?
| | Neutralization Tests | 1 | 2019 | 75 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2020 | 128 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2020 | 141 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 271 | 0.040 |
Why?
| | Cross Reactions | 1 | 2019 | 133 | 0.040 |
Why?
| | Seizures | 1 | 2023 | 426 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 475 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 889 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2019 | 166 | 0.040 |
Why?
| | Maternal Death | 1 | 2019 | 11 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1215 | 0.040 |
Why?
| | Maternal Mortality | 1 | 2019 | 46 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1477 | 0.040 |
Why?
| | Live Birth | 1 | 2019 | 66 | 0.040 |
Why?
| | Cities | 1 | 2019 | 133 | 0.040 |
Why?
| | Mosquito Control | 1 | 2019 | 28 | 0.040 |
Why?
| | Uterus | 1 | 2020 | 215 | 0.040 |
Why?
| | Educational Status | 1 | 2021 | 470 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 516 | 0.040 |
Why?
| | Stillbirth | 1 | 2019 | 72 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 2019 | 269 | 0.040 |
Why?
| | Species Specificity | 1 | 2019 | 585 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 386 | 0.040 |
Why?
| | Capacity Building | 1 | 2019 | 63 | 0.040 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 273 | 0.040 |
Why?
| | Odds Ratio | 1 | 2021 | 1070 | 0.040 |
Why?
| | Congenital Abnormalities | 1 | 2019 | 92 | 0.040 |
Why?
| | Mali | 1 | 2017 | 3 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2020 | 285 | 0.040 |
Why?
| | Anticonvulsants | 1 | 2020 | 217 | 0.030 |
Why?
| | Antibodies, Protozoan | 1 | 2017 | 36 | 0.030 |
Why?
| | CD8 Antigens | 1 | 2017 | 75 | 0.030 |
Why?
| | New Hampshire | 1 | 2017 | 4 | 0.030 |
Why?
| | United States | 2 | 2025 | 14841 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 101 | 0.030 |
Why?
| | Inflammation | 2 | 2019 | 2837 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 852 | 0.030 |
Why?
| | Immunity | 1 | 2017 | 143 | 0.030 |
Why?
| | Biomedical Research | 1 | 2023 | 692 | 0.030 |
Why?
| | Prenatal Care | 1 | 2019 | 294 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2016 | 148 | 0.030 |
Why?
| | Mastectomy | 1 | 2017 | 137 | 0.030 |
Why?
| | Body Weight | 1 | 2019 | 985 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 482 | 0.030 |
Why?
| | Immunization Schedule | 1 | 2016 | 197 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2014 | 48 | 0.030 |
Why?
| | Mothers | 1 | 2020 | 754 | 0.030 |
Why?
| | Graft Survival | 1 | 2017 | 535 | 0.030 |
Why?
| | Aged | 2 | 2024 | 23961 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 117 | 0.030 |
Why?
| | Qualitative Research | 1 | 2021 | 1386 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2017 | 706 | 0.030 |
Why?
| | Placenta | 1 | 2020 | 750 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1066 | 0.030 |
Why?
| | Biopsy | 1 | 2016 | 1129 | 0.030 |
Why?
| | Research Design | 1 | 2019 | 1139 | 0.020 |
Why?
| | Age Factors | 1 | 2020 | 3295 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1704 | 0.020 |
Why?
| | Mass Screening | 1 | 2020 | 1287 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2074 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2019 | 986 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 2389 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2475 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4193 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2691 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2757 | 0.020 |
Why?
| | Liver | 1 | 2017 | 1943 | 0.020 |
Why?
| | Home Care Services | 1 | 1971 | 257 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3566 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4295 | 0.020 |
Why?
| | Medicare | 1 | 1971 | 773 | 0.020 |
Why?
| | Mice | 1 | 2017 | 17787 | 0.010 |
Why?
| | Nebraska | 1 | 1971 | 18 | 0.010 |
Why?
|
|
Brickley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|